Antibody targeting of B7-H4 enhances the immune response in urothelial carcinoma

References

• Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–13. doi:10.1016/j.immuni.2013.07.012.
   PubMed Web of Science ®Google Scholar
• Podojil JR, Miller SD. Potential targeting of B7-H4 for the treatment of cancer. Immunol Rev. 2017;276(1):40–51. doi:10.1111/imr.2017.276.issue-1.
   PubMed Web of Science ®Google Scholar
• Zang X, Loke P, Kim J, Murphy K, Waitz R, Allison JP. B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci U S A. 2003;100(18):10388–10392. doi:10.1073/pnas.1434299100.
   PubMed Web of Science ®Google Scholar
• Ichikawa M. Role of B7-H1 and B7-H4 molecules in down-regulating effector phase of T-cell immunity: novel cancer escaping mechanisms. Front Biosci. 2005;10(1–3):2856–2860. doi:10.2741/1742.
   PubMedGoogle Scholar
• Podojil JR, Liu LN, Marshall SA, Chiang M-Y, Goings GE, Chen L, Langermann S, Miller SD. B7-H4Ig inhibits mouse and human T-cell function and treats EAE via IL-10/Treg-dependent mechanisms. J Autoimmun. 2013;44:71–81. doi:10.1016/j.jaut.2013.04.001.
   PubMed Web of Science ®Google Scholar
• Xu Y, Zhu S, Song M, Liu W, Liu C, Li Y, WANG M. B7-H4 expression and its role in interleukin-2/interferon treatment of clear cell renal cell carcinoma. Oncol Lett. 2014;7(5):1474–1478. doi:10.3892/ol.2014.1961.
   PubMed Web of Science ®Google Scholar
• Krambeck AE, Thompson RH, Dong H, Lohse CM, Park ES, Kuntz SM, Leibovich BC, Blute ML, Cheville JC, Kwon ED, et al. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A. 2006;103(27):10391–10396. doi:10.1073/pnas.0600937103.
   PubMed Web of Science ®Google Scholar
• Zhang L, Wu H, Lu D, Li G, Sun C, Song H, Li J, Zhai T, Huang L, Hou C, et al. The costimulatory molecule B7-H4 promote tumor progression and cell proliferation through translocating into nucleus. Oncogene. 2013;32(46):5347–5358. doi:10.1038/onc.2012.600.
   PubMed Web of Science ®Google Scholar
• Quandt D, Fiedler E, Boettcher D, Marsch W, Seliger B. B7-h4 expression in human melanoma: its association with patients’ survival and antitumor immune response. Clin Cancer Res. 2011;17(10):3100–3111. doi:10.1158/1078-0432.CCR-10-2268.
   PubMed Web of Science ®Google Scholar
• Mugler KC, Singh M, Tringler B, Torkko KC, Liu W, Papkoff J, Shroyer KR. B7-h4 expression in a range of breast pathology: correlation with tumor T-cell infiltration. Appl Immunohistochem Mol Morphol. 2007;15(4):363–370.
   PubMedGoogle Scholar
• Li Z-Y, Mou Y-G, Zhang X-H, Chen Y, Guo J-G, Yang S, Yang Q-Y, Chen Z-P. Clinical significance of B7-H4 expression in matched non-small cell lung cancer brain metastases and primary tumors. Onco Targets Ther. 2013;6:869–875. doi:10.2147/OTT.
   PubMed Web of Science ®Google Scholar
• Sun Y, Wang Y, Zhao J, Gu M, Giscombe R, Lefvert AK, Wang X. B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer. 2006;53(2):143–151. doi:10.1016/j.lungcan.2006.05.012.
   PubMed Web of Science ®Google Scholar
• Arigami T, Uenosono Y, Ishigami S, Hagihara T, Haraguchi N, Natsugoe S. Clinical significance of the B7-H4 coregulatory molecule as a novel prognostic marker in gastric cancer. World J Surg. 2011;35(9):2051–2057. doi:10.1007/s00268-011-1186-4.
   PubMed Web of Science ®Google Scholar
• Zhao L-W, Li C, Zhang R-L, Xue H-G, Zhang F-X, Zhang F, Gai X-D. B7-H1 and B7-H4 expression in colorectal carcinoma: correlation with tumor FOXP3+ regulatory T-cell infiltration. Acta Histochem. 2014;116(7):1163–1168. doi:10.1016/j.acthis.2014.06.003.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhao H, Zhu D, zhi Q, He S, Kuang Y, Li D, Zhang Z, Song S, Zhang L, et al. The coexpression and clinical significance of costimulatory molecules B7-H1, B7-H3, and B7-H4 in human pancreatic cancer. Onco Targets Ther. 2014;7:1465–1472. doi:10.2147/OTT.
   PubMed Web of Science ®Google Scholar
• Zang X, Thompson RH, Al-Ahmadie HA, Serio AM, Reuter VE, Eastham JA, Scardino PT, Sharma P, Allison JP. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A. 2007;104(49):19458–19463. doi:10.1073/pnas.0709802104.
   PubMed Web of Science ®Google Scholar
• Cheung SS, Ou D, Metzger DL, Meloche M, Ao Z, Ng SS, Owen D, Warnock GL. B7-H4 expression in normal and diseased human islet β cells. Pancreas. 2014;43(1):128–134. doi:10.1097/MPA.0b013e31829695d2.
   PubMed Web of Science ®Google Scholar
• Tringler B, Liu W, Corral L, Torkko KC, Enomoto T, Davidson S, Lucia MS, Heinz DE, Papkoff J, Shroyer KR, et al. B7-H4 overexpression in ovarian tumors. Gynecol Oncol. 2006;100(1):44–52. doi:10.1016/j.ygyno.2005.08.060.
   PubMed Web of Science ®Google Scholar
• Zhang -L-L, Shao S-L, Wu Y. Expressions of osteopontin and B7-H4 in epithelial ovarian neoplasm and their significance. Chin J Cancer. 2010;29(1):24–28. doi:10.5732/cjc.009.10158.
   Google Scholar
• Kryczek I, Wei S, Zhu G, Myers L, Mottram P, Cheng P, Chen L, Coukos G, Zou W. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res. 2007;67(18):8900–8905. doi:10.1158/0008-5472.CAN-07-1866.
   PubMed Web of Science ®Google Scholar
• Li J, Lee Y, Li Y, Jiang Y, Lu H, Zang W, Zhao X, Liu L, Chen Y, Tan H, et al. Co-inhibitory molecule B7 superfamily member 1 expressed by tumor-infiltrating myeloid cells induces dysfunction of anti-tumor CD8+ T cells. Immunity. 2018;48(4):773–86 e5. doi:10.1016/j.immuni.2018.03.018.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhu C, Curado MP, Zheng T, Boyle P. Changing patterns of bladder cancer in the USA: evidence of heterogeneous disease. BJU Int. 2012;109(1):52–56. doi:10.1111/bju.2012.109.issue-1.
   PubMed Web of Science ®Google Scholar
• Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O’Donnell PH, Balmanoukian A, Loriot Y, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet (London, England). 2016;387(10031):1909–1920. doi:10.1016/S0140-6736(16)00561-4.
   PubMed Web of Science ®Google Scholar
• Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee J-L, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–1026. doi:10.1056/NEJMoa1613683.
   PubMed Web of Science ®Google Scholar
• Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, Sher X, Liu XQ, Lu H, Nebozhyn M, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science (New York, NY. 2018;362(6411):eaar3593. doi:10.1126/science.aar3593.
   Google Scholar
• Fares CM, Van Allen EM, Drake CG, Allison JP, Hu-Lieskovan S. Mechanisms of resistance to immune checkpoint blockade: why does checkpoint inhibitor immunotherapy not work for all Patients? Am Soc Clin Oncol Educ Book Am Soc Clin Oncol. 2019;39(39):147–164. doi:10.1200/EDBK_240837.
   PubMedGoogle Scholar
• Marx V. Drilling into big cancer-genome data. Nat Methods. 2013;10(4):293–297. doi:10.1038/nmeth.2410.
   PubMed Web of Science ®Google Scholar
• Center BITGDA. Analysis overview for bladder urothelial carcinoma (primary solid tumor cohort) - 28. Broad Institute of MIT and Harvard; 2016. doi:10.7908/C19G5M58.
   Google Scholar
• Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics. 2011;12(1):323. doi:10.1186/1471-2105-12-323.
   PubMed Web of Science ®Google Scholar
• Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2018;174(4):1033. doi:10.1016/j.cell.2018.07.036.
   PubMed Web of Science ®Google Scholar
• Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Angell H, Fredriksen T, Lafontaine L, Berger A, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39(4):782–795. doi:10.1016/j.immuni.2013.10.003.
   PubMed Web of Science ®Google Scholar
• Faruki H, Mayhew GM, Serody JS, Hayes DN, Perou CM, Lai-Goldman M. Lung adenocarcinoma and squamous cell carcinoma gene expression subtypes demonstrate significant differences in tumor immune landscape. J Thorac Oncol. 2017;12(6):943–953. doi:10.1016/j.jtho.2017.03.010.
   PubMed Web of Science ®Google Scholar
• Glaser AP, Fantini D, Wang Y, Yu Y, Rimar KJ, Podojil JR, Miller SD, Meeks JJ. APOBEC-mediated mutagenesis in urothelial carcinoma is associated with improved survival, mutations in DNA damage response genes, and immune response. Oncotarget. 2018;9(4):4537–4548. doi:10.18632/oncotarget.v9i4.
   PubMedGoogle Scholar
• Lawlor N, Fabbri A, Guan P, George J, Karuturi RK. multiClust: an R-package for identifying biologically relevant clusters in cancer transcriptome profiles. Cancer Inform. 2016;15:103–114. doi:10.4137/CIN.S38000.
   PubMedGoogle Scholar
• Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15–21. doi:10.1093/bioinformatics/bts635.
   PubMed Web of Science ®Google Scholar
• Anders S, Pyl PT, Huber W. HTSeq–a Python framework to work with high-throughput sequencing data. Bioinformatics. 2015;31(2):166–169. doi:10.1093/bioinformatics/btu638.
   PubMed Web of Science ®Google Scholar
• Yu G, He Q-Y. ReactomePA: an R/Bioconductor package for reactome pathway analysis and visualization. Mol Biosyst. 2016;12(2):477–479. doi:10.1039/C5MB00663E.
   PubMedGoogle Scholar
• Fantini D, Glaser AP, Rimar KJ, Wang Y, Schipma M, Varghese N, Rademaker A, Behdad A, Yellapa A, Yu Y, et al. A Carcinogen-induced mouse model recapitulates the molecular alterations of human muscle invasive bladder cancer. Oncogene. 2018;37(14):1911–1925. doi:10.1038/s41388-017-0099-6.
   PubMed Web of Science ®Google Scholar
• Fantini D, Seiler R, Meeks JJ. Molecular footprints of muscle-invasive bladder cancer in smoking and nonsmoking patients. Urol Oncol. 2018;37(11):818–825.
   PubMed Web of Science ®Google Scholar
• Podojil JR, Chiang M-Y, Ifergan I, Copeland R, Liu LN, Maloveste S, Langermann S, Liebenson D, Balabanov R, Chi H, et al. B7-H4 modulates regulatory CD4 + T cell induction and function via ligation of a semaphorin 3a/plexin A4/neuropilin-1 complex. J Immunol. 2018;201(3):897–907. doi:10.4049/jimmunol.1700811.
   PubMed Web of Science ®Google Scholar
• Shin K, Lim A, Odegaard JI, Honeycutt JD, Kawano S, Hsieh MH, Beachy PA. Cellular origin of bladder neoplasia and tissue dynamics of its progression to invasive carcinoma. Nat Cell Biol. 2014;16(5):469–478. doi:10.1038/ncb2956.
   PubMed Web of Science ®Google Scholar
• Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, Schrock A, Campbell B, Shlien A, Chmielecki J, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34. doi:10.1186/s13073-017-0424-2.
   PubMed Web of Science ®Google Scholar
• Necchi A, Anichini A, Raggi D, Briganti A, Massa S, Luciano R, Colecchia M, Giannatempo P, Mortarini R, Bianchi M, et al. Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study. J Clin Oncol. 2018;JCO1801148.
   PubMed Web of Science ®Google Scholar
• Grande E, Galsky M, Arranz Arija JA, De Santis M, Davis ID, De Giorgi UFF, Mencinger M, Kikuchi E, Garcia Del Muro X, Gumus M, et al. LBA14_PRIMvigor130: efficacy and safety from a phase III study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC). Annals of Oncology. 2019;30(Supplement_5):v888–v889. doi:10.1093/annonc/mdz394.047.
   Google Scholar
• Kim J, Kwiatkowski D, McConkey DJ, Meeks JJ, Freeman SS, Bellmunt J, et al. The cancer genome atlas expression subtypes stratify response to checkpoint inhibition in advanced urothelial cancer and identify a subset of patients with high survival probability. Eur Urol. 2019;75(6):961–964. doi:10.1016/j.eururo.2019.02.017.
   PubMed Web of Science ®Google Scholar
• Sica GL, Choi I-H, Zhu G, Tamada K, Wang S-D, Tamura H, Chapoval AI, Flies DB, Bajorath J, Chen L, et al. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity. 2003;18(6):849–861. doi:10.1016/S1074-7613(03)00152-3.
   PubMed Web of Science ®Google Scholar
• Choi I-H, Zhu G, Sica GL, Strome SE, Cheville JC, Lau JS, Zhu Y, Flies DB, Tamada K, Chen L, et al. Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. J Immunol. 2003;171(9):4650–4654. doi:10.4049/jimmunol.171.9.4650.
   PubMed Web of Science ®Google Scholar
• Cao Q, Wang Y, Zheng D, Sun Y, Wang Y, Lee VW, Zheng G, Tan TK, Ince J, Alexander SI, et al. IL-10/TGF-β–modified macrophages induce regulatory T cells and protect against adriamycin nephrosis. J Am Soc Nephrol. 2010;21(6):933–942. doi:10.1681/ASN.2009060592.
   PubMed Web of Science ®Google Scholar
• Wei J, Loke P, Zang X, Allison JP. Tissue-specific expression of B7x protects from CD4 T cell-mediated autoimmunity. J Exp Med. 2011;208(8):1683–1694. doi:10.1084/jem.20100639.
   PubMed Web of Science ®Google Scholar
• Saito R, Smith CC, Utsumi T, Bixby LM, Kardos J, Wobker SE, Stewart KG, Chai S, Manocha U, Byrd KM, et al. Molecular subtype-specific immunocompetent models of high-grade urothelial carcinoma reveal differential neoantigen expression and response to immunotherapy. Cancer Res. 2018;78(14):3954–3968. doi:10.1158/0008-5472.Can-18-0173.
   PubMed Web of Science ®Google Scholar
• Salceda S, Tang T, Kmet M, Munteanu A, Ghosh M, Macina R, Liu W, Pilkington G, Papkoff J. The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation. Exp Cell Res. 2005;306(1):128–141. doi:10.1016/j.yexcr.2005.01.018.
   PubMed Web of Science ®Google Scholar
• Simon I, Katsaros D, Rigault de la Longrais I, Massobrio M, Scorilas A, Kim NW, Sarno MJ, Wolfert RL, Diamandis EP. B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression. Gynecol Oncol. 2007;106(2):334–341. doi:10.1016/j.ygyno.2007.03.035.
   PubMed Web of Science ®Google Scholar
• Qian Y, Shen L, Cheng L, Wu Z, Yao H. B7-H4 expression in various tumors determined using a novel developed monoclonal antibody. Clin Exp Med. 2011;11(3):163–170. doi:10.1007/s10238-010-0125-2.
   PubMed Web of Science ®Google Scholar
• Abadi YM, Jeon H, Ohaegbulam KC, Scandiuzzi L, Ghosh K, Hofmeyer KA, Lee JS, Ray A, Gravekamp C, Zang X, et al. Host b7x promotes pulmonary metastasis of breast cancer. J Immunol. 2013;190(7):3806–3814. doi:10.4049/jimmunol.1202439.
   PubMed Web of Science ®Google Scholar